JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 178 filers reported holding JUNO THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 1.38 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $220,981,000 | +8.6% | 4,834,370 | +6.6% | 0.01% | +10.0% |
| Q3 2017 | $203,431,000 | +58.5% | 4,534,784 | +5.6% | 0.01% | +42.9% |
| Q2 2017 | $128,357,000 | +38.3% | 4,294,296 | +2.6% | 0.01% | +40.0% |
| Q1 2017 | $92,838,000 | +37035.2% | 4,183,793 | +31399.7% | 0.01% | – |
| Q4 2016 | $250,000 | -38.4% | 13,282 | -1.9% | 0.00% | -100.0% |
| Q3 2016 | $406,000 | +9.7% | 13,533 | +40.6% | 0.00% | 0.0% |
| Q2 2016 | $370,000 | +496.8% | 9,626 | +491.6% | 0.00% | – |
| Q1 2016 | $62,000 | +34.8% | 1,627 | +55.4% | 0.00% | – |
| Q4 2015 | $46,000 | -43.2% | 1,047 | -47.6% | 0.00% | – |
| Q3 2015 | $81,000 | -23.6% | 2,000 | 0.0% | 0.00% | – |
| Q2 2015 | $106,000 | +783.3% | 2,000 | +930.9% | 0.00% | – |
| Q1 2015 | $12,000 | – | 194 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |